Table 1.
Covariates | Unmatched | Matched on propensity score | ||||
---|---|---|---|---|---|---|
New Users a | Glyburide (N=198,553) |
Glipizide (N=379,508) |
Standardized difference |
Glyburide (N=173,657) |
Glipizide (N=173,657) |
Standardized difference |
Sex, female | 101,307 (51.0%) | 166,997 (44.0%) | 0.141 | 78,013 (44.9%) | 80,048 (46.1%) | −0.024 |
Mean age (SD) | 55.0 (13.9) | 59.7 (12.7) | −0.353 | 57.9 (12.8) | 57.7 (12.5) | 0.016 |
Recorded history of | ||||||
Chronic kidney disease | 11,640 (5.9%) | 42,418 (11.2%) | −0.190 | 11,579 (6.7%) | 12,794 (7.4%) | −0.027 |
Serious Hypoglycemia | 4,532 (2.3%) | 18,754 (4.9%) | −0.143 | 4,433 (2.6%) | 4,657 (2.7%) | −0.008 |
Insulin | 14,903 (7.1%) | 34,011 (9.0%) | −0.069 | 13,692 (7.9%) | 13,988 (8.1%) | −0.006 |
Metformin | 66,450 (33.5%) | 183,560 (48.4%) | −0.303 | 65,680 (37.8%) | 67,446 (38.8%) | −0.021 |
Other antidiabetic drugs | 28,462 (14.3%) | 55,113 (14.5%) | 0.005 | 28,248 (16.3%) | 28,908 (16.6%) | −0.010 |
Combined Charlson/Elixhauser comorbidity score (SD) | 0.4 (1.7) | 0.7 (2.0) | −0.151 | 0.5 (1.7) | 0.6 (1.8) | −0.040 |
Health Service Utilization Intensity | ||||||
Number of unique drugs dispensed (SD) | 5.3 (4.3) | 6.3 (4.6) | −0.218 | 5.6 (4.4) | 5.7 (4.5) | −0.030 |
Number of dispensed prescriptions (SD) | 12.6 (13.1) | 14.2 (13.5) | −0.121 | 13.6 (13.7) | 14.0 (13.9) | −0.026 |
Number of inpatient hospital encounters (SD) | 0.1 (0.5) | 0.2 (0.6) | −0.094 | 0.1 (0.5) | 0.1 (0.5) | 0.000 |
Number of non-acute institutional encounters (SD) | 0.1 (0.9) | 0.1 (1.0) | 0.034 | 0.1 (1.0) | 0.1 (1.0) | 0.000 |
Number of emergency room encounters (SD) | 0.3 (0.7) | 0.3 (0.8) | 0.029 | 0.3 (0.8) | 0.3 (0.8) | 0.000 |
Number of ambulatory encounters (SD) | 6.9 (7.6) | 6.3 (7.8) | 0.082 | 6.5 (7.4) | 6.8 (8.7) | −0.037 |
Number of other ambulatory encounters (SD) b | 2.0 (3.5) | 2.7 (4.4) | −0.167 | 1.7 (3.3) | 1.9 (3.8) | −0.036 |
SD – Standard deviation.
Please note, one Data Partner removed a small number of users that moved to administrative services-only plans. Information from these users is included in Tables 1 and 2, but removed from subsequent tables.
Other ambulatory encounters included telemedicine and email consults, etc.